Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Non-cash Items (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Non-cash Items data on record, last reported at $32.3 million in Q4 2025.

  • For Q4 2025, Non-cash Items fell 13.4% year-over-year to $32.3 million; the TTM value through Dec 2025 reached $32.3 million, down 13.4%, while the annual FY2025 figure was $32.3 million, 13.4% down from the prior year.
  • Non-cash Items reached $32.3 million in Q4 2025 per APLS's latest filing, down from $37.3 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $317.0 million in Q4 2022 and bottomed at $32.3 million in Q4 2025.
  • Average Non-cash Items over 5 years is $186.5 million, with a median of $253.9 million recorded in 2023.
  • Peak YoY movement for Non-cash Items: skyrocketed 191.53% in 2021, then crashed 85.31% in 2024.
  • A 5-year view of Non-cash Items shows it stood at $291.8 million in 2021, then increased by 8.64% to $317.0 million in 2022, then decreased by 19.9% to $253.9 million in 2023, then tumbled by 85.31% to $37.3 million in 2024, then decreased by 13.4% to $32.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-cash Items were $32.3 million in Q4 2025, $37.3 million in Q4 2024, and $253.9 million in Q4 2023.